The genitourinary cancer space has seen a lot of updates in the past 5-10 years, but where are they all coming from so suddenly? Oncology Nursing News spoke with Michael Lai, ARNP, a nurse practitioner at Seattle Cancer Care Alliance, about how the genitourinary cancer space has been able to have so many updates recently.
In the genitourinary cancer space, there have been a lot of updates to follow in the past 5 years. At the 3rd Annual School of Nursing Oncology, we spoke with Michael Lai, ARNP, a nurse practitioner at Seattle Cancer Care Alliance, about why he thinks there have been so many updates recently.
TRANSCRIPTION
I think that it's sort of a coalescence of a number of different things, timing, maybe a little bit of luck, and there's just a lot more interest in bladder cancer these days. It's a deadly disease when it's metastatic, and we're trying to find options that go beyond the first and second line that can really prove to have some survival benefit. For prostate cancer, it's such a common ubiquitous disease amongst men, and so, it just makes sense to continue the research in this realm and provide all the options that we can.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes vs Chemo in Urothelial Cancer
April 20th 2024Patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin plus pembrolizumab experienced a reduction in the risk for disease progression or death vs chemotherapy.